An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors

Trial Profile

An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs BAL 101553 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Basilea Pharmaceutica
  • Most Recent Events

    • 10 Aug 2017 Completion of patient recruitment into this trial is expected in the first half of 2018 according to a Basilea Pharmaceutica media release.
    • 06 Jun 2017 According to a Basilea Pharmaceuticals media release, the company expected completion of dose-escalation towards the end of 2017.
    • 06 Jun 2017 According to a Basilea Pharmaceuticals media release, interim data was presented at the the American Society of Clinical Oncology (ASCO) annual meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top